Sort   by:  
 Page size 
ProteomicsCo-translational assembly counteracts promiscuous interactions
During the co-translational assembly of protein complexes, a fully synthesized subunit engages with the nascent chain of a newly synthesized interaction partner. Such events are thought to contribute to productive assembly, but their exact physiological relevance remains underexplored. Here, we exam...
ORGANISM(S): Saccharomyces cerevisiae (Baker's yeast) 
2022-02-11 | PXD028413 | Pride
Protein complex assembly Co-translational assembly Nuclear pore complex 
ProteomicsCo-translational assembly counteracts promiscuous interactions
During the co-translational assembly of protein complexes, a fully synthesized subunit engages with the nascent chain of a newly synthesized interaction partner. Such events are thought to contribute to productive assembly, but their exact physiological relevance remains underexplored. Here, we exam...
ORGANISM(S): Saccharomyces cerevisiae (Baker's yeast) 
2022-02-11 | PXD030626 | Pride
Co-translational assembly Proteomics 
ProteomicsDissecting the RAD51–BRC4 Interaction Landscape through Integrative Molecular Simulations and Experimental Biophysics
The interaction between the RAD51 and BRCA2 proteins is central to homologous recombination (HR), a crucial pathway ensuring high-fidelity DNA repair. Recruitment of RAD51 involves eight highly conserved regions on BRCA2, named BRC repeats. The interaction between the fourth BRC repeat (BRC4) and th...
ORGANISM(S): Homo sapiens (Human) Escherichia coli 
2025-10-29 | PXD060867 | Pride
Genomicsena-DATASET-RTL-03-05-2017-12:40:06:735-476 - samples
RNAseq of LC2AD with AD80 or DMSO Plenker et al., Mechanistic insight into RET kinase inhibitors targeting the DFG-out conformation in RET-rearranged cancer
EGAD00001003316 | EGA
GenomicsDrugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
Oncogenic fusion events have been identified in a broad range of tumors. Among them, RET rearrangements represent distinct and potentially druggable targets that are recurrently found in lung adenocarcinomas. We provide further evidence that current anti-RET drugs may not be potent enough to induce ...
EGAS00001002335 | EGA
UnknownTwo Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Not available
S-EPMC10794000 | biostudies-literature
Sort   by:  
 Page size